Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.

Amgen was established in Australia in 1991 and is renowned for carrying out leading-edge clinical research and development. The Australian operations have become and integral part of Amgen's global development program.

The company currently markets four products in Australia (Aranesp^®, Neulasta^®, NEUPOGEN^®, Sensipar^®) and is recognised for its outstanding contributions to educational initiatives for healthcare professionals and patients.